The freshly announced multibillion biotech buyout of Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) for more than $5 billion in equity value may be a bit misleading if you consider that it is effectively a split deal.  Nonetheless Wall Street investors and traders love buyout announcements and one buyout usually leads these investors to look for the next buyout candidate(s).

24/7 Wall St. wanted to take a look at several other possible merger candidates in the biotech and emerging pharma sector.  Our focus is generally on the companies which have a $1 billion potential buyout value to a suitor because Big Pharma players generally cannot waste time on too many small deals unless they can be rapidly expanded.  We would make a reminder that Wall Street standalone price targets often do not value a company at the same rate as a buyer.  Case in point: Amylin’s $31.00 cash buyout by Bristol-Myers Squibb Co. (NYSE: BMY) for about 50% more than what Wall Street’s Thomson Reuters consensus price target was.

One company which routinely arises as a buyout name is Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX).  Its $11.5 billion value is getting on the higher side of a biotech M&A, and its shares have been extremely volatile based upon good news flow followed by bad news flow.  The Thomson Reuters consensus target is $67.65 on Vertex versus a $54.60 price today and versus a high of $66.10.

This company is likely too expensive to buy on a nominal basis, but Celgene Corporation (NASDAQ: CELG) has now corrected by about 20% from its highs after massive growth was met by mixed drug news.  The market cap of the shares is almost $29 billion and Wall Street analysts have a price target of $76.09 on the stock against a current share price of $64.50 and against a high of $80.42.

One company which we have targeted in the past as a potential target for its fight against infections from healthcare facilities is Cubist Pharmaceuticals Inc. (NASDAQ: CBST).  The success of Cubicin and other partnerships helped shares double over the last couple of years and the move may have put too much of a premium in this one.  A management shakeup may rekindle some M&A hopes here and the premium valuation still only comes to a market cap of $2.45 billion.  At $38.75 the consensus target from Wall Street is almost $49.00.

Read Also: The Next (non-Biotech) Mergers of 2012

The $2 billion Amarin Corporation plc (NASDAQ: AMRN) is up over 4% on word that it may be a takeout candidate as well.  At $15.00, Wall Street has almost a $23 price target on this ahead of a decision on its triglycerides treatment under FDA review.

VIVUS Inc. (NASDAQ: VVUS) is not moving at all on buyout hopes, but with it believed to have the best chance of being the weight loss drug its $28.60 price generates a market value of more than $2.8 billion. Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) is a weight-loss rival worth some $1.8 billion now, but the enthusiasm has backed off after understanding what its position in weight loss may be around a 2013 timing.

Another player worth note has been Pharmacyclics Inc. (NASDAQ: PCYC).  It appears to be the top gainer in biotech year to date and the company is now worth about $4 billion.  After another near-7% gain to $58.36 on Monday, this one’s price target is $49.71 from Wall Street analysts.  We have heard no credible rumors here but the reality is that a gain of this magnitude speaks for itself. Its large oncology pipeline appears to be driving significant value and high hopes here.

Two players which routinely came up as hopeful M&A targets were Human Genome Sciences Inc. (NASDAQ: HGSI) with a $2.7 billion value today and Dendreon Corporation (NASDAQ: DNDN) with a $1.1 billion value. Human Genome has been fighting off a low-price bid from GlaxoSmithKline (NYSE: GSK).  Both of these companies have fallen from grace and HGSI’s BENLYSTA for Lupus and Dendreon’s PROVENGE for advanced prostate cancer have both lagged expectations.

One smaller name which surfaced as a possible buyout candidate after a FDA Orphan Drug designation for its Hepatitis treatment is Medgenics, Inc. (NYSEMKT: MDGN).  Its market value is only $100 million, but various forms of Hepatitis can make for very successful acquisitions if handled properly.

A Piper Jaffray note reported by theflyonthewall listed the following companies as possible buyout targets:

• Affymetrix Inc. (NASDAQ: AFFX), but its shares are lower after a Goldman Sachs downgrade. This one’s $4.55 share price generates only a $320 million market cap, and Thomson Reuters has a consensus target of roughly $5.60 after its recent acquisition of eBioscience.
• BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) hit a new high of $41.11 today and its market value is about $4.75 billion.  At $40.95, the consensus target is $42.00.
• Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) is up almost 2% and just under $9.50, and its market cap is $674 million with a consensus target on the stock of $13.00.
• Theravance Inc. (NASDAQ: THRX) was up 7.9% at $23.98 and its market value if $2.1 billion comes along with a Wall Street consensus price target of $24.50.

As you have probably figured out, there are no free lunches in biotech.  Literally none.  Betting on these companies for the sake of a buyout can be rather painful.  Still, we have seen time after time that the biotech and emerging pharma sectors consolidate time after time.

JON C. OGG

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.